Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma.

In rats with diethylnitrosamine (DENA)-induced hepatocellular carcinoma (HCC), we studied in vivo gene transfer efficiency using intraportal injections of recombinant adenovirus carrying the lacZ reporter gene (AdCMVlacZ) and the therapeutic efficacy of adenovirus-mediated transfer of the thymidine kinase gene of the herpes simplex virus (HSV-tk) followed by ganciclovir (GCV) administration. DENA was very effective in inducing HCC but also stimulated nontumor cell replication, as shown by proliferating cell nuclear antigen (PCNA) staining. The study of in vivo gene transfer efficiency in tumor-bearing rats showed that nontumor tissue and small tumor nodules were transduced effectively whereas a poor transduction rate was noted in large tumor nodules. Concerning therapeutic efficacy, three groups of rats with established HCC were studied: group A and B received intraportally recombinant adenovirus carrying HSV-tk (AdCMVtk) or AdCMVlacZ, respectively, and 2 days after GCV was given intraperitoneally for 9 days; group C received only saline. Of the rats from groups B and C, 100% and 93% respectively, exhibited multiple HCC tumor nodules at end of the study. In contrast, a complete regression of tumor was observed in 63% of animals from group A. This group showed significant elevation of serum transaminases and a diffuse hepatotoxic lesion in liver tissue; histological signs of regeneration were observed in surviving animals. Nine out of 19 rats from group A died during the treatment period. We conclude that (i) in the DENA model of HCC, tumoral cells can be destroyed in vivo by the HSV-tk/GCV system despite poor transduction of large tumor nodules, suggesting that toxic metabolites generated by nontumor cells may exert a bystander effect on tumor tissue; (ii) significant hepatoxicity and a high mortality rate occurred in HSV-tk/GCV-treated rats; these side effects appear to be due to the fact that in DENA-treated livers enhanced cell proliferation was present not only in tumor nodules but also in nontumor parenchyma, leading to GCV sensitization of both tissues; (iii) our results have implications concerning the efficacy and potential risks of the HSV-tk/GCV system in the treatment of human HCC.

[1]  M. Perricaudet,et al.  In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. , 1996, Human gene therapy.

[2]  D. Klatzmann,et al.  Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect". , 1996, Cancer gene therapy.

[3]  W. Zhang,et al.  Adenoviral delivery of recombinant DNA into transgenic mice bearing hepatocellular carcinomas. , 1996, Human gene therapy.

[4]  S. Kuriyama,et al.  Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma , 1995, Hepatology.

[5]  S. Kaneko,et al.  Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. , 1995, Cancer research.

[6]  K. Wills,et al.  Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. , 1995, Cancer gene therapy.

[7]  Z. Xiang,et al.  Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[8]  C. Qian,et al.  Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus‐mediated gene transfer of herpes simplex virus thymidine kinase , 1995, Hepatology.

[9]  H. Hwang,et al.  Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. , 1995, American journal of respiratory cell and molecular biology.

[10]  S. Nagataki,et al.  Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. , 1995, Cancer research.

[11]  Moolten Fl.  Drug sensitivity ("suicide") genes for selective cancer chemotherapy. , 1994 .

[12]  X. Breakefield,et al.  Enhanced cytotoxicity of antiviral drugs mediated by adenovirus directed transfer of the herpes simplex virus thymidine kinase gene in rat glioma cells. , 1994, Cancer gene therapy.

[13]  A. Venook.  Treatment of hepatocellular carcinoma: too many options? , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Busuttil,et al.  The role of multimodal therapy in the treatment of hepatocellular carcinoma , 1994, Cancer.

[15]  E. Furth,et al.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[16]  F. Gage,et al.  Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. Fan,et al.  Prognostic significance of proliferating cell nuclear antigen expression in hepatocellular carcinoma , 1994, Cancer.

[18]  B. Davidson,et al.  Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. , 1994, Cancer research.

[19]  R. Grossman,et al.  Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Gordon,et al.  Delayed morbidity and mortality of albumin/SV40 T-antigen transgenic mice after insertion of an alpha-fetoprotein/herpes virus thymidine kinase transgene and treatment with ganciclovir. , 1994, Human gene therapy.

[21]  R. Warnick,et al.  In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. , 1993, Human gene therapy.

[22]  S. Freeman,et al.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. , 1993, Cancer research.

[23]  R. Vile,et al.  Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. , 1993, Cancer research.

[24]  D. Klatzmann,et al.  Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Z. Ram,et al.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. , 1992, Science.

[26]  K. Sikora,et al.  Gene therapy for cancer , 1992, The Lancet.

[27]  P Grasso,et al.  Dose and time relationships for tumor induction in the liver and esophagus of 4080 inbred rats by chronic ingestion of N-nitrosodiethylamine or N-nitrosodimethylamine. , 1991, Cancer research.

[28]  M. Doffoel,et al.  Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: Results of a western comparative study in 60 patients , 1991, Hepatology.

[29]  F. Moolten,et al.  Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. , 1990, Journal of the National Cancer Institute.

[30]  J. Swenberg,et al.  Dose response of hepatocyte replication in rats following continuous exposure to diethylnitrosamine. , 1989, Cancer research.

[31]  H. Barbason,et al.  Proliferation of preneoplastic lesions after discontinuation of chronic DEN feeding in the development of hepatomas in rat. , 1981, British Journal of Cancer.

[32]  H. Barbason,et al.  Liver cell control after discontinuation of DENA feeding in hepatocarcinogenesis. , 1981, European journal of cancer.

[33]  H. Rabes,et al.  Cell kinetics of hepatocytes during the preneoplastic period of diethylnitrosamine-induced liver carcinogenesis. , 1979, Cancer research.

[34]  M. Rajewsky.  Changes in DNA synthesis and cell proliferation during hepatocarcinogenesis by diethylnitrosamine. , 1967, European journal of cancer.

[35]  M. Rajewsky,et al.  Liver Carcinogenesis by Diethylnitrosamine in the Rat , 1966, Science.

[36]  C. Breedis,et al.  The blood supply of neoplasms in the liver. , 1954, The American journal of pathology.

[37]  W. F. Anderson.  Gene therapy for cancer. , 1994, Human gene therapy.

[38]  M. Gore,et al.  Gene therapy for cancer. , 1994, European journal of cancer.

[39]  Z. Ram,et al.  In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. , 1993, Cancer research.

[40]  H. Taniguchi,et al.  Blood supply and drug delivery to primary and secondary human liver cancers studied with in vivo bromodeoxyuridine labeling , 1993, Cancer.

[41]  D. Sarma,et al.  Hepatocarcinogenesis: a dynamic cellular perspective. , 1987, Laboratory investigation; a journal of technical methods and pathology.